Article
The effects of anagrelide on human megakaryocytopoiesis
1 Oct 1997
Abstract excerpt
Anagrelide, an inhibitor of platelet aggregation, decreases the number of platelets in normal subjects and in patients with myeloproliferative disorders. We describe studies aimed at discovering the general mechanism(s) by which anagrelide acts. We examined three hypotheses: (1) anagrelide shortens platelet survival, (2) anagrelide inhibits the proliferation of megakaryocytic-committed progenitor cells (CFU-M),...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
